Company: ATRA
Filing Date: 2025-03-07
Form Type: 10-K
Source: 0000950170-25-035507
Chunk: 196

Company: Atara Biotherapeutics, Inc.
Filing Date: 2025-03-07
Form: 10-K
Item: Item 1B
Chunk 196
---
59,282

    2,010

    Increase (decrease) in cash, cash equivalents and restricted cash

    (811
    )

    (67,101
    )

    Cash, cash equivalents and restricted cash at beginning of period

    25,987

    93,088

    Cash, cash equivalents and restricted cash at end of period
     
    $
    25,176

    $
    25,987

    Non-cash investing and financing activities

    Property and equipment purchases included in accounts payable and other  accrued liabilities
     
    $
    —

    $
    132

    Accrued costs related to ATM facilities
     
    $
    —

    $
    78

    Proceeds from issuance of common stock through ATM facilities not yet received
     
    $
    —

    $
    114

    Supplemental cash flow disclosure

    Cash paid for interest
     
    $
    685

    $
    447

    Cash paid for income taxes
     
    $
    24

    $
    2

See accompanying notes to the consolidated financial statements.

102

Atara Biotherapeutics, Inc. 

Notes to Consolidated Financial Statements

1.Description of BusinessAtara Biotherapeutics, Inc. (Atara, we, our or the Company) was incorporated in August 2012 in Delaware. Atara is a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr Virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune disease.Our most advanced T-cell immunotherapy program, tab-cel® (tabelecleucel), has received marketing authorization approval under the proprietary name Ebvallo™ by the European Commission (EC) for commercial sale and use in the European Economic Area (EEA), by the Medicines and Healthcare products Regulatory Agency (MHRA) for commercial sale and use in the United Kingdom (UK) and by Swissmedic for commercial sale and use in Switzerland. Tab-cel is currently in Phase 3 development in the US. In October 2021, we entered into a commercialization agreement (Pierre Fabre Commercialization Agreement) with Pierre Fabre Medicament (Pierre Fabre), as amended in September 2022, pursuant to which we granted to Pierre Fabre an exclusive, field-limited license to commercialize and distribute Ebvallo in Europe and select emerging markets in the Middle